PASW:NASDAQPing An Biomedical Co., Ltd. Analysis

The stock is trading at $0.174, well below its 20‑day SMA of 0.166 and its 50‑day SMA of 0.162, and dramatically under the 200‑day SMA of 0.449, indicating a long‑term downtrend. Momentum signals are mixed: the RSI sits at 53.5 (neutral) while the MACD line is marginally above the signal line, giving a bullish histogram hint. Volume is on an increasing trend, yet price volatility is extreme at over 75% in the past 30 days, and beta of 1.16 suggests heightened market sensitivity. Fundamentals are severely distressed – revenue has collapsed by 62%, gross margin is a mere 2.8%, operating margin is negative 69.6%, and the company carries a staggering debt‑to‑equity ratio above 23. Cash reserves of just $1.17 M cannot meaningfully offset $10.5 M of debt, leading to a max drawdown of roughly -96%. Valuation multiples are low (price‑to‑book 0.53, price‑to‑sales 0.63), but the balance sheet weakness and cash‑flow deficits dominate the risk picture. The sector—consumer cyclical textile manufacturing—adds cyclical pressure, while geographic exposure across China, Hong Kong, Cambodia and Europe introduces medium regulatory and currency challenges. Overall, the stock appears priced at a discount relative to peers but is burdened by profound operational and financial headwinds.